RLMD

Relmada Therapeutics Inc. (RLMD) | Rumor.io

Relmada Therapeutics

RLMD

Attention (50-day avg)0%

Attention rank (50-day avg)#2,227

Bullish sentiment (50-day avg)92%

Price to earnings ratio-2.62

Market capitalization404.3M

Earnings per share-0.91

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-57.4M

Social

What share of all stock conversation is about RLMD?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% 0

Sep 11

The CEO and CFO of Relmada Therapeutics, Sergio Traversa and Maged Shenouda, have collectively purchased $1.67M worth of company shares, with Traversa buying $828,000 and Shenouda buying $843,000.
This insider buying is a bullish signal, as executives are using their own money to increase their positions in the company.
The purchases have sparked a 13% gap in the stock, with a short ratio of 7.83 and a float signal squeeze readiness, indicating institutional accumulation.

Generated by AI

Sentiment

Of the messages about RLMD that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	98.11% -1.89	82.02% -0.31
Bearish	—	—	1.89% new	17.98% +0.31

Bullish· Mar 10

The company is presenting at a major healthcare conference, which is a key catalyst for the stock's surge.
The asset is gaining momentum due to promising clinical trials and potential FDA approval for its cancer treatments.
Institutional interest is building, with the stock holding higher levels and building pressure for a potential breakthrough to $12.60.

Bearish· Mar 9

$RLMD's bladder cancer data is competitive with another company's ($IBRX) at a lower valuation.
$RLMD's price action is forming a falling wedge pattern, potentially indicating a continuation of the downtrend.
$RLMD has been unable to sustain a rally above $6.50, and is still trading below its 200-day moving average.

Generated by AI

Topics

Of the messages about RLMD that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	66.98%
Analysts	—	—	0%	4.37%
Technical Analysis	—	—	0%	23.19%
Controversies	—	—	0%	0%
Earnings	—	—	0%	0.68%
Macro	—	—	0%	4.77%

Announcements· Mar 10

Relmada Therapeutics, Inc. ($RLMD) reported positive 12-month Phase 2 interim data for NDV-01 in Non-Muscle Invasive Bladder Cancer, showing a 76% complete response rate.
The company has secured $160M in oversubscribed private placement financing, providing runway for Phase 3 trials.
$RLMD is presenting at the Leerink Partners Global Healthcare Conference, confirming market share expansion potential and signaling high-conviction institutional interest.

Technical Analysis· Mar 9

$RLMD is expected to retest the 7.22 daily resistance zone, potentially leading to a rally into 7.4/7.5.
The stock is showing a falling wedge pattern on the 5-minute chart, indicating a potential solid rally from its current base.
Buyers are in control, and the stock has a strong bullish signal at 6.45-6.50, with a potential push to $7 or even $8.

Generated by AI

Community

Of the messages about RLMD, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	100%	45.36%	44.1%
Newcomers	—	0%	54.64%	55.9%

Regulars· Mar 9

The company's bladder cancer data (phase 2) has reported positive results, which could be a competitive blow to other companies in the space, particularly those with bloated valuations.
Relmada Therapeutics has completed an oversubscribed $160M private placement financing at $4.75 per share, with participating investors receiving roughly 29.5 million common shares and pre-funded warrants.
The stock is looking to retest its daily resistance zone at $7.22, a key level for potential upside into the $7.4-$7.5 range.

Newcomers· Mar 10

The newcomer community is focused on the potential for Relmada Therapeutics, Inc. ($RLMD) to gain momentum due to promising clinical trials and FDA approval on the horizon for its cancer treatments.
There is a strong emphasis on the company's upcoming presentation at the Leerink Partners Global Healthcare Conference, which is seen as a catalyst for institutional interest and a potential breakout.
The discussion is centered around the stock's potential for a high-conviction, volatile biotech play, with a focus on the company's runway into Phase 3 and the possibility of a pharma partner.

Generated by AI

News

Relmada: 'Hold' Based On Needed NVD-01 Manufacturing Push For IND YE2026 And Sepranolone Advancement

15d agoSeeking Alpha

Relmada CEO Sergio Traversa buys 200,000 shares for $828,000

19d agoInvesting.com

Relmada Therapeutics CFO Maged Shenouda buys $843,990 in shares

19d agoInvesting.com

Relmada Therapeutics Shares Rise After CEO, CFO Buy 200,000 Shares Each

Relmada Therapeutics (RLMD) shares were up nearly 11% in afternoon trading on Friday after the compa

19d agoYahoo Finance

Relmada Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare Conference

CORAL GABLES, Fla., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced that senior management will participate in one-on-one meetings at the Wells Fargo 21st Annual Healthcare Conference being held in Boston, MA, from September 8 - 10, 2026. Wells Fargo 21st Annual Healthcare Conference DetailsFormat: One-o

29d agofinance.yahoo.com

After Plunging 18.5% in 4 Weeks, Here's Why the Trend Might Reverse for Relmada Therapeutics (RLMD)

Relmada Therapeutics (RLMD) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

29d agoYahoo Finance

Also Discussed

Investors talking about RLMD also mention

#	Name	Attention
1	Axsome Therapeutics IncAXSM	0.01%0
2	GH Research PLCGHRS	0%0
3	Nuvation Bio Inc.NUVB	0%0
4	Shattuck Labs, Inc.STTK	0%new
5	TERN - Terns Pharmaceuticals, Inc.	——
6	PMV Pharmaceuticals, Inc.PMVP	0%0
7	Xilio Therapeutics, Inc.XLO	0%0
8	PSTX - Poseida Therapeutics, Inc.	——
9	CytomX Therapeutics, Inc.CTMX	0%0
10	ETNB - 89bio, Inc.	——

Relmada Therapeutics Inc.

Healthcare
Biotechnology

Relmada Therapeutics Inc. is a clinical-stage biotechnology company focused on developing therapies for oncology and central nervous system disorders. Its current pipeline centers on product candidates designed to address areas of significant unmet medical need, including NDV-01 for non-muscle invasive bladder cancer and sepranolone for neurological and compulsivity-related conditions. The company also advances esmethadone, a novel NMDA receptor antagonist being evaluated for central nervous system indications such as major depressive disorder and other related disorders. Relmada Therapeutics Inc. operates as a research-driven drug developer, using targeted clinical programs to explore new treatment options across cancer, psychiatric, and neurological care. Headquartered in Coral Gables, Florida, the company remains focused on late-stage development of proprietary therapies intended to expand treatment possibilities in specialized disease areas.

Website

Location

2222 Ponce de Leon Blvd.

Coral Gables, FL, 33134

United States

Social

What share of all stock conversation is about RLMD?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% 0

Sep 11

The CEO and CFO of Relmada Therapeutics, Sergio Traversa and Maged Shenouda, have collectively purchased $1.67M worth of company shares, with Traversa buying $828,000 and Shenouda buying $843,000.
This insider buying is a bullish signal, as executives are using their own money to increase their positions in the company.
The purchases have sparked a 13% gap in the stock, with a short ratio of 7.83 and a float signal squeeze readiness, indicating institutional accumulation.

Generated by AI

Sentiment

Of the messages about RLMD that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	98.11% -1.89	82.02% -0.31
Bearish	—	—	1.89% new	17.98% +0.31

Bullish· Mar 10

The company is presenting at a major healthcare conference, which is a key catalyst for the stock's surge.
The asset is gaining momentum due to promising clinical trials and potential FDA approval for its cancer treatments.
Institutional interest is building, with the stock holding higher levels and building pressure for a potential breakthrough to $12.60.

Bearish· Mar 9

$RLMD's bladder cancer data is competitive with another company's ($IBRX) at a lower valuation.
$RLMD's price action is forming a falling wedge pattern, potentially indicating a continuation of the downtrend.
$RLMD has been unable to sustain a rally above $6.50, and is still trading below its 200-day moving average.

Generated by AI

Topics

Of the messages about RLMD that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	66.98%
Analysts	—	—	0%	4.37%
Technical Analysis	—	—	0%	23.19%
Controversies	—	—	0%	0%
Earnings	—	—	0%	0.68%
Macro	—	—	0%	4.77%

Announcements· Mar 10

Relmada Therapeutics, Inc. ($RLMD) reported positive 12-month Phase 2 interim data for NDV-01 in Non-Muscle Invasive Bladder Cancer, showing a 76% complete response rate.
The company has secured $160M in oversubscribed private placement financing, providing runway for Phase 3 trials.
$RLMD is presenting at the Leerink Partners Global Healthcare Conference, confirming market share expansion potential and signaling high-conviction institutional interest.

Technical Analysis· Mar 9

$RLMD is expected to retest the 7.22 daily resistance zone, potentially leading to a rally into 7.4/7.5.
The stock is showing a falling wedge pattern on the 5-minute chart, indicating a potential solid rally from its current base.
Buyers are in control, and the stock has a strong bullish signal at 6.45-6.50, with a potential push to $7 or even $8.

Generated by AI

Community

Of the messages about RLMD, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	100%	45.36%	44.1%
Newcomers	—	0%	54.64%	55.9%

Regulars· Mar 9

The company's bladder cancer data (phase 2) has reported positive results, which could be a competitive blow to other companies in the space, particularly those with bloated valuations.
Relmada Therapeutics has completed an oversubscribed $160M private placement financing at $4.75 per share, with participating investors receiving roughly 29.5 million common shares and pre-funded warrants.
The stock is looking to retest its daily resistance zone at $7.22, a key level for potential upside into the $7.4-$7.5 range.

Newcomers· Mar 10

The newcomer community is focused on the potential for Relmada Therapeutics, Inc. ($RLMD) to gain momentum due to promising clinical trials and FDA approval on the horizon for its cancer treatments.
There is a strong emphasis on the company's upcoming presentation at the Leerink Partners Global Healthcare Conference, which is seen as a catalyst for institutional interest and a potential breakout.
The discussion is centered around the stock's potential for a high-conviction, volatile biotech play, with a focus on the company's runway into Phase 3 and the possibility of a pharma partner.

Generated by AI

Relmada Therapeutics

Social

Sep 11

Bullish· Mar 10

Bearish· Mar 9

Announcements· Mar 10

Technical Analysis· Mar 9

Regulars· Mar 9

Newcomers· Mar 10

Relmada: 'Hold' Based On Needed NVD-01 Manufacturing Push For IND YE2026 And Sepranolone Advancement

Relmada CEO Sergio Traversa buys 200,000 shares for $828,000

Relmada Therapeutics CFO Maged Shenouda buys $843,990 in shares

Relmada Therapeutics Shares Rise After CEO, CFO Buy 200,000 Shares Each

Relmada Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare Conference

After Plunging 18.5% in 4 Weeks, Here's Why the Trend Might Reverse for Relmada Therapeutics (RLMD)

Also Discussed

Relmada Therapeutics Inc.

Company Information

Location

Relmada: 'Hold' Based On Needed NVD-01 Manufacturing Push For IND YE2026 And Sepranolone Advancement

Relmada CEO Sergio Traversa buys 200,000 shares for $828,000

Relmada Therapeutics CFO Maged Shenouda buys $843,990 in shares

Relmada Therapeutics Shares Rise After CEO, CFO Buy 200,000 Shares Each

Relmada Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare Conference

After Plunging 18.5% in 4 Weeks, Here's Why the Trend Might Reverse for Relmada Therapeutics (RLMD)

Also Discussed

Social

Sep 11

Bullish· Mar 10

Bearish· Mar 9

Announcements· Mar 10

Technical Analysis· Mar 9

Regulars· Mar 9

Newcomers· Mar 10